Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

{ "Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin", "This study is looking at how a dermal filler called Restylane-L affects the quality of your skin's support structure (extracellular matrix) in people aged 30 to 50. Researchers will inject small amounts of Restylane-L and a saline solution (vehicle) into your forearm. They want to see if Restylane-L helps improve the skin's extracellular matrix compared to the saline. The study aims to enroll 15 participants and is currently unclear about its recruitment status. Success will be measured by looking at changes in the extracellular matrix of your skin using special stains about four weeks after the injections.", "design": "This interventional study plans to enroll 15 participants between 30 and 50 years old. It will compare the effects of Restylane-L to a saline vehicle.", "commitments": "You would receive four injections in one forearm: two of Restylane-L and two of a saline solution. The effects on your skin will be assessed approximately 4 weeks after the injections.", "compensation": "Not stated in the trial record.", "follow_up": "Your skin's extracellular matrix will be measured approximately 4 weeks after the injections.", }

Study design: Not specified.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

Active, Not Recruiting

NAAges 30–50InterventionalTreatment

University of Michigan

~15 participants

Updated 2026-08-17 on ClinicalTrials.gov

What's tested:Restylane-LVehicle

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Extracellular Matrix (ECM) deposition as measured using histological stain(s) of skin

Measured over Approximately 4 weeks

Conditions

Photoaging

NCT06195605

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

University of Michigan
Ann Arbor, Michiganno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Gary Fisher · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Subjects must understand and sign the informed consent prior to participation

Subjects must be in generally good health

Subjects must be able and willing to comply with the requirements of the protocol

Exclusion

Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy

Individuals with bleeding disorders

Tend to heal poorly or form very thick scars called keloids

Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.

Individuals with active inflammation or infection of the skin, including active herpes infection.

Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection.

History of allergies to gram positive bacterial proteins

Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.

Have an active inflammation or infection of the skin near the site of injection

Are taking any medications that suppress your immune system

Have severe allergies to medications or other things that we believe might make participation unsafe for you

Have a history of connective tissue diseases, such as:

rheumatoid arthritis

scleroderma

polymyositis/dermatomyositis

systemic lupus erythematosus (SLE)

What this trial measures

Extracellular Matrix (ECM) deposition as measured using histological stain(s) of skinApproximately 4 weeks
Reported as a semi-quantitative grade. The grading scale is 1-4. The higher the number to increased ECM deposition.

Trialytics